<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="487">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04345523</url>
  </required_header>
  <id_info>
    <org_study_id>ConPlas-19</org_study_id>
    <nct_id>NCT04345523</nct_id>
  </id_info>
  <brief_title>Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients</brief_title>
  <acronym>ConPlas-19</acronym>
  <official_title>Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cristina Avendaño Solá</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 278 patients are planned.&#xD;
&#xD;
      All patients will be in an early-stage of COVID-19. They must be adults and hospitalized.&#xD;
&#xD;
      In this study, all participating patients will receive the standard treatment provided&#xD;
      according to the current treatment protocols for coronavirus disease. In addition to this&#xD;
      treatment, each patient will be randomly assigned to receive additional treatment with&#xD;
      convalescent plasma transfusion (CP; blood plasma from patients who have been cured of&#xD;
      coronavirus), or continue with standard treatment but without adding transfusion.&#xD;
&#xD;
      50% of the chances of additional treatment with CP, and 50% of the chances of receiving only&#xD;
      the standard treatment for coronavirus.&#xD;
&#xD;
      The duration of the study shall be one month from the assignment of the treatment.&#xD;
&#xD;
      The patient and the doctor will know the treatment assigned.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center, randomized, clinical trial with two arms to study the efficacy and safety of&#xD;
      passive immunotherapy with CP compared to a control of standard of care (SOC).&#xD;
&#xD;
      All trial participants will receive SOC:&#xD;
&#xD;
        -  Treatment arm: Pathogen-reduced CP from patients recovered from COVID-19, whom, for the&#xD;
           purpose of this trial, are herein designated as donors.&#xD;
&#xD;
        -  Control arm: SOC for COVID-19.&#xD;
&#xD;
      Randomization among the two arms will be 1:1 and will be stratified per center. Of note, in&#xD;
      the current status of a worldwide pandemic for which we have no approved vaccines or drugs,&#xD;
      for the purpose of this trial SOC would also accept any drugs that are being used in clinical&#xD;
      practice (e.g. lopinavir/ritonavir; darunavir/cobicistat; hydroxy/chloroquine, tocilizumab,&#xD;
      etc.), other than those used as part of another clinical trial.&#xD;
&#xD;
      The study is planned with a sequential design. Interim analyses: comprehensive safety data&#xD;
      monitoring analyses will be conducted when 20%, 40%, 60% and 80% of patients, or at the&#xD;
      discretionary DSMB criteria when needed. A DSMB charter will be set before the trial&#xD;
      initiation where criteria for prematurely stopping the trial due to safety issues will be&#xD;
      set. Interim analyses will be predefined upfront based on the DSMB recommendations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 ratio for CP: Control arm. Also, approximately 140-200 CP donors.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Category Changes in the &quot;7-Ordinal Scale&quot;</measure>
    <time_frame>15 days</time_frame>
    <description>Proportion of patients in categories 5, 6 or 7 of the 7-point ordinal scale at day 15 7- Ordinal scale:&#xD;
Not hospitalized, no limitations on activities.&#xD;
Not hospitalized, limitation on activities.&#xD;
Hospitalized, not requiring supplemental oxygen.&#xD;
Hospitalized, requiring supplemental oxygen.&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices.&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO.&#xD;
Death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to category 5, 6 or 7 of the &quot; 7-Ordinal scale&quot;</measure>
    <time_frame>29 days</time_frame>
    <description>Time to change from baseline category to worsening into 5,6 or 7 categories of the &quot;7-Ordinal scale&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to an improvement of one category from admission in the &quot;7-Ordinal scale&quot;</measure>
    <time_frame>29 days</time_frame>
    <description>Time to an improvement of one category from admission in the &quot;7-Ordinal scale&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status at day 30 in the &quot;11-Ordinal scale&quot;</measure>
    <time_frame>30 days</time_frame>
    <description>Status at day 30 in the &quot;11-Ordinal scale&quot;&#xD;
&quot;11-Ordinal scale&quot; :&#xD;
0. Uninfected ; no viral RNA detected.&#xD;
Asymptomatic; viral RNA detected, limitation on activities.&#xD;
Symptomatic; independent&#xD;
Symptomatic; assistance needed&#xD;
Hospitalized, no oxygen therapy.&#xD;
Hospitalized, oxygen by mask or nasal prongs&#xD;
Oxygen by mask or nasal prongs&#xD;
Intubation and mechanical ventilation, pO2/FiO2 ≥150 or SpO2/FiO2 ≥200&#xD;
Mechanical ventilation pO2/FIO2 &lt;150 (SpO2/FiO2 &lt;200) or vasopressors&#xD;
Mechanical ventilation pO2/FiO2 &lt;150 and vasopressors, dialysis, or ECMO&#xD;
Dead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status at day 15 and 30 in the &quot;11-Ordinal scale&quot;</measure>
    <time_frame>30 days</time_frame>
    <description>Status at day 15 and 30 in the &quot;11-Ordinal scale&quot;&#xD;
Status at day 15 and 30 in the &quot;11-Ordinal scale&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first deterioration</measure>
    <time_frame>60 days</time_frame>
    <description>Time to first deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the ranking in the &quot;7-Ordinal scale&quot; from baseline to days 3,5,8,11,15,29 and 60</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change in the ranking in the &quot;7-Ordinal Scale&quot; from baseline to days 3,5,8,11,15,29 and 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the ranking in the &quot;11-Ordinal scale from baseline to days 3,5,8,11,15,29 and 60.</measure>
    <time_frame>60 days</time_frame>
    <description>Mean change in the ranking in the &quot;11- Ordinal scale&quot; from baseline to days 3,5,8,11,15,29 and 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality of any cause at 15 days</measure>
    <time_frame>15 days</time_frame>
    <description>Rate of mortality of any cause within first 15 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality of any cause at 28 days (day 29)</measure>
    <time_frame>28 days (day 29)</time_frame>
    <description>Rate of mortality of any cause within first 28 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality of any cause at 60 days</measure>
    <time_frame>60 days</time_frame>
    <description>Rate of mortality of any cause within first 60 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation free days</measure>
    <time_frame>29 days</time_frame>
    <description>days free from oxygen supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>29 days</time_frame>
    <description>days free from mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization (days)</measure>
    <time_frame>60 days</time_frame>
    <description>days of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion-related adverse events</measure>
    <time_frame>60 days</time_frame>
    <description>Infusion-related adverse events Cumulative incidence of serious adverse events (SAEs) Cumulative incidence of Grade 3 and 4 adverse events (AEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>60 days</time_frame>
    <description>cumulative incidence of Grade 3 and 4 adverse events (AEs) Cumulative incidence of serious adverse events (SAEs) Cumulative incidence of Grade 3 and 4 adverse events (AEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibodies levels in CP donors recovered from COVID-19</measure>
    <time_frame>3 months</time_frame>
    <description>Quantitative total antibodies and neutralizing antibody activity against SARSCoV-2 in the sera from donors and patients using viral pseudotypes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>Days 1,3,5,8,11,15, 29 and 60</time_frame>
    <description>Change in PCR for SARS-CoV-2 in naso/oropharyngeal swabs at baseline and at discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>Days 1,3,5,8,11,15,29 and 60</time_frame>
    <description>Change in PCR for SARS-CoV-2 in blood on Days 3,5,8,11,15,29 and 60 (while hospitalized) until two of them are negative consecutively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of thrombotic arterial events</measure>
    <time_frame>60 days</time_frame>
    <description>incidence of thrombotic arterial events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of thrombotic venous events</measure>
    <time_frame>60 days</time_frame>
    <description>incidence of thrombotic venous events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of rehospitalizations</measure>
    <time_frame>60 days</time_frame>
    <description>rehospitalizations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">278</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pathogen-reduced CP from patients recovered from COVID-19, whom, for the purpose of this trial, are herein designated as donors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care (SOC) for COVID-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood and derivatives.</intervention_name>
    <description>Administration of fresh plasma from donor immunized against COVID-19</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Convalescent Plasma from patients recovered from COVID-19</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of care for the treatment of COVID-19 in hospitalized patients</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>SOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent prior to performing study procedures. Witnessed oral consent&#xD;
             will be accepted in order to avoid paper handling. Written consent by patient or&#xD;
             representatives will be obtained as soon as possible.&#xD;
&#xD;
          2. Male or female adult patient ≥18 years of age at time of enrolment.&#xD;
&#xD;
          3. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR in&#xD;
             naso/oropharyngeal swabs or any other relevant specimen in the ongoing COVID-19&#xD;
             symptomatic period. Alternative test (i.e antigenic tests) are also acceptable as&#xD;
             laboratory confirmation if their adequate specificity has been accepted by the&#xD;
             sponsor.&#xD;
&#xD;
          4. Patients requiring hospitalization for COVID-19 without mechanical ventilation&#xD;
             (invasive or non-invasive) or high flow oxygen devices and at least one of the&#xD;
             following:&#xD;
&#xD;
               -  Radiographic evidence of pulmonary infiltrates by imaging (chest x-ray, CT scan,&#xD;
                  etc.), OR&#xD;
&#xD;
               -  Clinical assessment (evidence of rales/crackles on exam) AND SpO2 ≤ 94% on room&#xD;
                  air that requires supplemental oxygen.&#xD;
&#xD;
          5. No more than 7 days between the onset of symptoms (fever or cough) and treatment&#xD;
             administration day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Requiring mechanical ventilation (invasive or non-invasive) or high flow oxygen&#xD;
             devices.&#xD;
&#xD;
          2. More than 7 days since symptoms (fever or cough).&#xD;
&#xD;
          3. Participation in any other clinical trial of an experimental treatment for COVID-19.&#xD;
&#xD;
          4. In the opinion of the clinical team, progression to death is imminent and inevitable&#xD;
             within the next 24 hours, irrespective of the provision of treatments.&#xD;
&#xD;
          5. Any incompatibility or allergy to the administration of human plasma.&#xD;
&#xD;
          6. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR &lt;30).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Avendaño Solá, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Puerta de Hierro Majadahonda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Duarte Palomino, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Puerta de Hierro Majadahonda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Ramos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta de Hierro Majadahonda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Luis Bueno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta de Hierro Majadahonda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inmaculada Casas Flecha, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Nacional de Microbiología, Instituto de Salud Carlos III</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Avendaño Solá, MD, PhD</last_name>
    <phone>+34 91 191 64 79</phone>
    <email>cavendano@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Ramón Paño Pardo, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>José Ramón Paño Pardo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Antonio Moreno Chulilla, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Mútua Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Leganés</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel Cervero Jiménez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Miguel Cervero Jiménez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Barberana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Muñez, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Elena Muñez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Luis Bueno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Príncipe de Asturias</name>
      <address>
        <city>Meco</city>
        <state>Madrid</state>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristina Hernández Guitiérrez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cristina Hernández Gutiérrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Flores Ballester, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Javier Blanch Sancho, MD</last_name>
    </contact>
    <investigator>
      <last_name>José Javier Blanch Sancho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Gutiérrez Gamarra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hernando Knobel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hernando Knobel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriela Ene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Lourdes Porras Leal, MD</last_name>
    </contact>
    <investigator>
      <last_name>María Lourdes Porras Leal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María del Castillo Jarilla Fernández, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>Donostia</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Antonio Iribarren, MD</last_name>
    </contact>
    <investigator>
      <last_name>José Antonio Iribarren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Carlos Vallejo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Doctor Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoni Castro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antoni Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Millán, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Doctor Negrín</name>
      <address>
        <city>Las Palmas</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Saenz Pelaez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Oscar Saenz Pelaez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luisa Guerra Domínguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de León</name>
      <address>
        <city>León</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Luis Mostaza Fernández, MD</last_name>
    </contact>
    <investigator>
      <last_name>José Luis Mostaza Fernández, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Vidán Estévez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Jover Saenz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alfredo Jover Saenz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Manuel Sánchez Villegas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro</name>
      <address>
        <city>Logroño</city>
        <zip>26006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Antonio Oteo Revuelta, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jose Antonio Oteo Revuelta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Sola Lapeña, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio de Santos Gil, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ignacio de Santos Gil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Vicuña Andrés, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Machado, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marina Machado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Anguita Velasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Martínez Sanz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Javier Martínez Sanz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gemma Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Estrada Pérez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vicente Estrada Pérez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Isabel Saez Serrano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Lora Tamayo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jaime Lora Tamayo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Liz Paciello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Villares, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paula Villares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaime Pérez de Oteyza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quironsalud Pozuelo</name>
      <address>
        <city>Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu de Manresa. Fundación Althaia</name>
      <address>
        <city>Manresa</city>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonia Flor Pérez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Albert Altés Hernández, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonia Flor Pérez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Colunga, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dolores Colunga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose María García Gala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Murillas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Javier Murillas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Ballester, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra (CUN). Sedes Pamplona y Madrid</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Ramón Yuste, MD</last_name>
    </contact>
    <investigator>
      <last_name>José Ramón Yuste, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esther Pena Carbó, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gracia Ruiz de Alda, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Gracia Ruiz de Alda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alicia Aranguren Azparren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moncef Belhassen García, MD</last_name>
    </contact>
    <investigator>
      <last_name>Moncef Belhassen García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga López Villar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria del Carmen Fariñas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria del Carmen Fariñas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Íñigo Romón Alonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Toledo</name>
      <address>
        <city>Toledo</city>
        <zip>45007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Sánchez Castaño, MD</last_name>
    </contact>
    <investigator>
      <last_name>Angel Sánchez Castaño, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angel Luis Pajares Herraiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Puchades Gimeno, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francisco Puchades Gimeno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armando V. Mena-Durán, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Jesús Dueñas Gutierrez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carlos Jesús Dueñas Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ignacio de la Fuente Graciani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estibaliz Jarauta Simón, MD</last_name>
    </contact>
    <investigator>
      <last_name>Estibaliz Jarauta Simón, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victoria Paz González Rodríguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>Cristina Avendaño Solá</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Convalescent Plasma</keyword>
  <keyword>SOC</keyword>
  <keyword>CP</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>PD that underlie the results reported in this article, after deidenficiation (text, tables, figures, and appendices) will be shared. The data will be available after main report is published.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data will have access to the data upon reasonable request.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

